|Articles|May 1, 2011
Study Completion Times
Author(s)TTC
Improved study completion times represents one of the most critical areas for clinical development organizations. Previous TTC research has demonstrated that paying sites more on a cost per patient basis does not improve study completions times.
Advertisement
Improved study completion times represents one of the most critical areas for clinical development organizations. Previous TTC research has demonstrated that paying sites more on a cost per patient basis does not improve study completions times.
Other variables, such as study and protocol design, or whether a CRO or sponsor directly runs the fieldwork may be important. According to http://clinicaltrials.gov , TTC subscribers conduct over 76% of all commercial trials around the world. A detailed analysis of study completion results for over 2,500 Phase III studies demonstrates that whether a CRO or sponsor company runs the study has no bearing on study completion times. It might be hypothesized that CRO-run studies would be slightly slower to complete because of the added information step between sponsor company and CRO embedded in outsourced studies from study start to study completion.
Still, study design factors such as the number of countries in a study, had clear affects on completion times. There is, however, no difference whether a CRO or sponsor company manages the study. —TTC (for more information, contact help@ttc-llc.com ).
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How Recent Policy Changes Could Impact Clinical Research
September 10th 2025
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
eClinical Technology: Misconceptions, Challenges, and Opportunities
3
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
4
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
5